Cancer Immunology, Immunotherapy

, Volume 57, Issue 8, pp 1185–1195 | Cite as

Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1

  • Junko Matsuzaki
  • Feng Qian
  • Immanuel Luescher
  • Shashikant Lele
  • Gerd Ritter
  • Protul A. Shrikant
  • Sacha Gnjatic
  • Lloyd J. Old
  • Kunle OdunsiEmail author
Original Article


NY-ESO-1 is frequently expressed in epithelial ovarian cancer (EOC) and elicits spontaneous humoral and cellular immune responses in a proportion of EOC patients. The identification of NY-ESO-1 peptide epitopes with dual HLA-class I and class II specificities might be useful in vaccination strategies for generating cognate CD4+ T cell help to augment CD8+ T cell responses. Here, we describe two novel NY-ESO-1-derived MHC class I epitopes from EOC patients with spontaneous humoral immune response to NY-ESO-1. CD8+ T cells derived from NY-ESO-1 seropositive EOC patients were presensitized with a recombinant adenovirus encoding NY-ESO-1or pooled overlapping peptides. These epitopes, ESO127–136 presented by HLA-A68 molecule, and ESO127–135 restricted by HLA-Cw15 allele, are located within ESO119–143, a promiscuous HLA-class II region containing epitopes that bind to multiple HLA-DR alleles. The novel epitopes were naturally processed by APC or naturally presented by tumor cell lines. In addition, these epitopes induced NY-ESO-1-specific CTL in NY-ESO-1 seropositive EOC patients. Together, the results indicate that ESO119–143 epitope has dual HLA classes I and II specificities, and represents a potential vaccine candidate in a large number of cancer patients.


Epithelial ovarian cancer Tumor immunity NY-ESO-1 CD8 Epitope MHC class I 



This work was supported by Cancer Research Institute/Ludwig Institute for Cancer Research Cancer Vaccine Collaborative Grant; and by Anna-Marie Kellen Clinical Investigator Award of the Cancer Research Institute, NY (K. O.).


  1. 1.
    Aldener-Cannava A, Olerup O (2001) HLA-DPB1 typing by polymerase chain reaction amplification with sequence-specific primers. Tissue Antigens 7:287–299CrossRefGoogle Scholar
  2. 2.
    Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE (2006) Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res 66:1912–1916PubMedCrossRefGoogle Scholar
  3. 3.
    Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M (2000) Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164:3902–3912PubMedGoogle Scholar
  4. 4.
    Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA 2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78PubMedCrossRefGoogle Scholar
  5. 5.
    Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, Gahery-Ségard H, Guillet JG, Ménez A, Georges B, Maillère B (2002) HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 169:6928–6934PubMedGoogle Scholar
  6. 6.
    Chen W, McCluskey J (2006) Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 95:203–247PubMedCrossRefGoogle Scholar
  7. 7.
    Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914–1918PubMedCrossRefGoogle Scholar
  8. 8.
    Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, Gnjatic S, Harris PE, Bisikirska B, Guillaume P, Cerottini JC, Hesdorffer CS, Old LJ, Valmori D (2002) Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813–1022PubMedGoogle Scholar
  9. 9.
    Gnjatic S, Atanackovic D, Jäger E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ (2003) Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100:8862–8867PubMedCrossRefGoogle Scholar
  10. 10.
    Gnjatic S, Jäger E, Chen W, Altorki NK, Matsuo M, Lee SY, Chen Q, Nagata Y, Atanackovic D, Chen YT, Ritter G, Cebon J, Knuth A, Old LJ (2002) CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 99:11813–11818PubMedCrossRefGoogle Scholar
  11. 11.
    Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ (2000) Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 97:10917–10922PubMedCrossRefGoogle Scholar
  12. 12.
    Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4+ T cells in the antitumor immune response. J Exp Med 188:2357–2368PubMedCrossRefGoogle Scholar
  13. 13.
    Jackson H, Dimopoulos N, Mifsud NA, Tai TY, Chen Q, Svobodova S, Browning J, Luescher I, Stockert L, Old LJ, Davis ID, Cebon J, Chen W (2006) Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. J Immunol 176:5908–5917PubMedGoogle Scholar
  14. 14.
    Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270PubMedCrossRefGoogle Scholar
  15. 15.
    Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760–4765PubMedCrossRefGoogle Scholar
  16. 16.
    Kudela P, Janjic B, Fourcade J, Castelli F, Andrade P, Kirkwood JM, El-Hefnawy T, Amicosante M, Maillere B, Zarour HM (2007) Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol 179:7932–7940PubMedGoogle Scholar
  17. 17.
    Lethé B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T (1998) LAGE-1, a new gene with tumor specificity. Int J Cancer 76:903–908PubMedCrossRefGoogle Scholar
  18. 18.
    Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076–6083PubMedGoogle Scholar
  19. 19.
    Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S (2007) Vaccination with an NY-ESO-1 peptide of dual HLA class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses in ovarian cancer patients. Proc Natl Acad Sci USA 104:12837–12842PubMedCrossRefGoogle Scholar
  20. 20.
    Ohkuri T, Sato M, Abe H, Tsuji K, Yamagishi Y, Ikeda H, Matsubara N, Kitamura H, Nishimura T (2007) Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. Cancer Sci 98:1092–1098PubMedCrossRefGoogle Scholar
  21. 21.
    Qian F, Gnjatic S, Jäger E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood A, Old LJ, Odunsi K (2004) Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun 4:12PubMedGoogle Scholar
  22. 22.
    Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP (2003) Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9:1377–1382PubMedCrossRefGoogle Scholar
  23. 23.
    Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1PubMedGoogle Scholar
  24. 24.
    Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337–339PubMedCrossRefGoogle Scholar
  25. 25.
    Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT (2004) Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nat Immunol 5:1143–1148PubMedCrossRefGoogle Scholar
  26. 26.
    Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354PubMedCrossRefGoogle Scholar
  27. 27.
    Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339–342PubMedCrossRefGoogle Scholar
  28. 28.
    Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P (2006) A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol Immunother 55:644–652PubMedCrossRefGoogle Scholar
  29. 29.
    Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753–756PubMedCrossRefGoogle Scholar
  30. 30.
    Valmori D, Lévy F, Godefroy E, Scotto L, Souleimanian NE, Karbach J, Tosello V, Hesdorffer CS, Old LJ, Jager E, Ayyoub M (2007) Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin Immunol 122:163–172PubMedCrossRefGoogle Scholar
  31. 31.
    Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51–88PubMedCrossRefGoogle Scholar
  32. 32.
    Yewdell JW (2006) Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25:533–543PubMedCrossRefGoogle Scholar
  33. 33.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM (2002) NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62:213–218PubMedGoogle Scholar
  34. 34.
    Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM (2000) NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 60:4946–4952PubMedGoogle Scholar
  35. 35.
    Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF (2001) CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964–3969PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Junko Matsuzaki
    • 1
  • Feng Qian
    • 1
  • Immanuel Luescher
    • 2
  • Shashikant Lele
    • 3
  • Gerd Ritter
    • 4
  • Protul A. Shrikant
    • 5
  • Sacha Gnjatic
    • 4
  • Lloyd J. Old
    • 4
  • Kunle Odunsi
    • 1
    Email author
  1. 1.Departments of Gynecologic Oncology and ImmunologyRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Ludwig Institute for Cancer ResearchLausanneSwitzerland
  3. 3.Department of Gynecologic OncologyRoswell Park Cancer InstituteBuffaloUSA
  4. 4.New York Branch at Memorial Sloan-Kettering Cancer CenterLudwig Institute for Cancer ResearchNew YorkUSA
  5. 5.Department of ImmunologyRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations